Open an account

scPharmaceuticals

SCPH · NASDAQ

Price unavailable right now.

No price history for this range.

About SCPH

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 162 full-time employees. The company went IPO on 2017-11-17. The firm is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

Employees
163
Headquarters
Burlington, Massachusetts
Listed
Nov 17, 2017
Sector
Health Care
Industry
Pharmaceuticals
Website
scpharmaceuticals.com

SCPH key statistics

This section is temporarily unavailable. Refresh to try again.

SCPH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 15.5% on average.

  1. Q3 FY23: reported -$0.41 per share against an estimate of -$0.3721
  2. Q4 FY23: reported -$0.35 per share against an estimate of -$0.4272
  3. Q1 FY24: reported -$0.36 per share against an estimate of -$0.4457
  4. Q2 FY24: reported -$0.44 per share against an estimate of -$0.4223
  5. Q3 FY24: reported -$0.75 per share against an estimate of -$0.3024
  6. Q4 FY24: reported -$0.35 per share against an estimate of -$0.3859
  7. Q1 FY25: reported -$0.37 per share against an estimate of -$0.304
  8. Q2 FY25: reported -$0.34 per share against an estimate of -$0.304

SCPH news

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRY, SCPH, WKHS on Behalf of Shareholders

  • Press releaseBusiness Wire

    SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCO, VRNT, SCPH on Behalf of Shareholders

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, BKH, MURA, SCPH on Behalf of Shareholders

  • Press releaseBusiness Wire

    SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

  • Vandana Singh

    MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCPH, VTLE, CRGY on Behalf of Shareholders

  • Press releaseBusiness Wire

    SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders

Similar companies

Companies in the same industry as scPharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.